Press release
Endometrial Cancer Therapeutics Market Worldwide Industry Analysis - P&S Intelligence
endometrial cancer therapeutics market
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market
Diagnosis of endometrial cancer at an early stage is done by normal pelvic examination. But, when the cancer reaches advanced stage then biopsy or pap smear are used as diagnostic methods. The treatment options available to the patients are chemotherapy, radiation therapy and surgery, providing maximum opportunities to the global endometrial cancer therapeutics market.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market/report-sample
Though, chemotherapy is projected to have the maximum share in the global endometrial cancer therapeutics market owing to high adoption rate of chemotherapy over surgical treatment and radiation therapy in oncology. Also, carboplatin and paclitaxel are recommended as chemotherapeutic agents for first line of therapy in majority of the cases, which increases demand for these products. FDA recently approved IXEMPRA (ixabepilone) for use in endometrial cancer treatment which is likely to increase the growth of market during in the future.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=endometrial-cancer-treatment-market
Some of the key players operating in the global endometrial cancer therapeutics market are AstraZeneca Plc., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc. and R-Pharm-US LLC.
About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometrial Cancer Therapeutics Market Worldwide Industry Analysis - P&S Intelligence here
News-ID: 1697309 • Views: …
More Releases from P&S Intelligence
U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
According to the latest market research study published by P&S Intelligence, the U.S. Environmental, Social, and Governance (ESG) investments market is experiencing a significant surge, with projections indicating an increase from $6.5 trillion in 2024 to an estimated $16.0 trillion by 2032. This represents a robust compound annual growth rate (CAGR) of 12.1% over the forecast period.
According to a comprehensive analysis by P&S Intelligence, the market's expansion is driven…
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sec …
According to the latest market research study published by P&S Intelligence, the U.K. facility management market is poised for significant growth, with projected revenues reaching USD 2,743.3 million in 2024 and expected to soar to USD 6,038.4 million by 2030, reflecting a robust CAGR of 14.1% during the forecast period.
This expansion is fueled by a surge in demand across both public and private sectors. According to the RICS U.K.…
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by O …
According to the latest market research study published by P&S Intelligence, the U.S. point-of-sale (POS) software market, valued at USD 4.7 billion in 2024, is poised for significant growth over the coming years, with projections estimating it will reach USD 9.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. This growth is attributed to rapid technological advancements, a surge in mobile and cloud-based POS systems,…
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, an …
According to the latest market research study published by P&S Intelligence, the global industrial starches market is poised for significant growth, with a projected increase from USD 110.3 billion in 2024 to USD 169.9 billion by 2030, at a robust compound annual growth rate (CAGR) of 7.5%. Industrial starches play a crucial role in diverse sectors, including food, pharmaceuticals, and paper, driven by their unique properties such as stabilizing, thickening,…
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
